, Volume 1, Issue 2, pp 109–115 | Cite as

Glibenclamide, a New Sulphonylurea: Whither Oral Hypoglycaemic Agents?

  • Alexander Marble
Guest Editorial


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ruiz, CL.; Silva, L.L., and Libenson, L.: Contribución al estudio sobre la composición química de la insulina. Estudio de algunos cuerpos sintéticos sulfurados con acción hipoglucemiante. Revista de la Sociedad argentina de biología 6: 134 (1930).Google Scholar
  2. 2.
    Savagnone, L.: Sulfamidi e recambio idrocarbonato influenza della somministrazione di sulfamidi sul tasso glicemico in condizioni normali e patológiche. Settimana médica 29: 1005(1941).Google Scholar
  3. 3.
    Loubatières, A.: Analyse du mécanisme de l’action hypoglycémiante du p-amino-benzène sulfamido thiodiazol (2254 R.P.). Comptes rendus des séances de la Société de biologie et de ses filiales 138: 766 (1944).Google Scholar
  4. 4.
    Janbon, M.; Chaptal, J.; Vedel, A. et Schaap, J.: Accidents hypoglycémiques graves par un sulfamido-thiodiazol (le V.K. 57 ou 2254 R.P.). Montpellier médical 21s-22: 441 (1942).Google Scholar
  5. 5.
    Franke, H. und Fuchs, J.: Ein neues antidiabetisches Prinzip. Deutsche medizinische Wochenschrift 80: 1449 (1955).PubMedCrossRefGoogle Scholar
  6. 6.
    Creutzfeldt, W. and Söling, H.-D.: Oral treatment of Diabetes: A Clinical and Experimental Review, p. 94 (Springer, Berlin 1961).CrossRefGoogle Scholar
  7. 7.
    Aumüller, W.; Bänder, A.; Heerdt, R.; Muth, K.; Pfaff, W.; Schmidt, F.H.; Weber, H. und Weyer, R.: Ein neues hochwirksames orales Antidiabeticum. Arzneimittel-Forschung 16: 1640 (1966).PubMedGoogle Scholar
  8. 8.
    Johnson, B.F.; Bhatia, CK.; Rzeszotarski, W.J., and Wolff, F.W.: Preliminary clinical evaluation of gli-benclamide in treatment of diabetes mellitus. Diabetes 19: 579 (1970).PubMedGoogle Scholar
  9. 9.
    Raptis, S., Rau, R.M.; Schröder, K.E.; Faulhaber, J.D., and Pfeiffer, E.F.: Comparative study of insulin secretion following repeated administration of glucose, tolbutamide and glibenclamide (HB 419) in diabetic and non-diabetic human subjects. Hormone and Metabolic Research 1 (Suppl. 1): 65 (1969).Google Scholar
  10. 10.
    Levine, R. and Pfeiffer, E.F. (Eds.): HB 419 A new oral antidiabetic drug. (Papers presented at the Tegernsee Conference, in Rottach-Egern, Germany, January 27s-29, 1969.) Hormone and Metabolic Research i (Suppl. 1): 1–92 (1969).Google Scholar
  11. 11.
    Müller, R.; Bauer, G.; Schröder, R., and Saito, S.: Summary report of clinical investigation of the oral antidiabetic drug HB 419. Hormone and Metabolic Research 1 (Suppl. 1): 88 (1969).Google Scholar
  12. 12.
    Goldner, M.G. and Prout, T.E.: The University Group Diabetes Program: The effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes. 1. Design and methods (Abstract). Diabetes 19 (Suppl. 1): 387 (1970).Google Scholar
  13. 13.
    Prout, T.E. and Goldner, M.G.: The University Group Diabetes Program: The effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes. 2. Findings at baseline (Abstract). Diabetes 19 (Suppl. 1): 374 (1970). 3. Course and mortality (Abstract). Ibid. 375.Google Scholar
  14. 14.
    The University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 19 (Suppl. 2): 747–830 (1970).Google Scholar
  15. 15.
    Balodimos, M. C.; Gleason, R.E.; Bradley, R.F.; Krall, L.P., and Marble, A.: Causes of death after long-term sulfonylurea therapy. Submitted for publication.Google Scholar
  16. 16.
    Balodimos, M.C.; Rippey, J.H., and Marble, A.: Causes of death and pathological findings in diabetic patients treated with sulfonylurea compounds. Proceedings of the 7th International Congress of Gerontology, Vienna 3 (No. 447): 281 (1966).Google Scholar
  17. 17.
    Balodimos, M.C.; Marble, A.; Rippey, J.H.; Legg, M.A.; Kuwabara, T., and Gleason, R.E.: Pathological findings after long-term sulfonylurea therapy. Diabetes 17: 503 (1968).PubMedGoogle Scholar
  18. 18.
    Balodimos, M.C. and Marble, A.: Diabetic angiopathy and sulfonylurea therapy. Minnesota Medicine 57: 1341 (1968).Google Scholar
  19. 19.
    Keen, H. and Jarrett, R.J.: Discussion of paper by Prout and Goldner (ref. 13). See also Keen, H.; Jarrett, R.J.; Chlouverakis, C, andBoyns, D.R.: The effect of treatment of moderate hyperglycemia on the incidence of arterial disease. Postgraduate Medical Journal 44 (Suppl. Dec): 960 (1968). Also Keen, #.: Minimal diabetes and arterial disease: prevalence and the effect of treatment; in Camerini-Davalos and Cole Early Diabetes, p. 437 (Academic Press, New York 1970).Google Scholar
  20. 20.
    Paasikivi, J.: Discussion of paper by Prout and Goldner (ref. 13). See also Paasikivi, J: Long-term tolbutamide treatment after myocardial infarction. Acta Medica Scandinavica 757 (Suppl. 507): 1–82 (1970).Google Scholar
  21. 21.
    Hardin, R.D.: Statement on treatment of diabetes. Diabetes 19: 527 (1970).Google Scholar
  22. 22.
    American Medical News, November 2, p. 6 (1970).Google Scholar
  23. 23.
    Marble, A.: Angiopathy in diabetes; an unsolved problem. Diabetes 16: 825 (1967).PubMedGoogle Scholar
  24. 24.
    American Medical News, November 23, p. 2 (1970).Google Scholar
  25. 25.
    Editorial: Are antidiabetic drugs dangerous? British Medical Journal 4: 444 (1970).Google Scholar

Copyright information

© Adis International Limited 1971

Authors and Affiliations

  • Alexander Marble
    • 1
  1. 1.New England Deaconess Hospital and Harvard Medical SchoolJoslin ClinicBostonUSA

Personalised recommendations